<DOC>
	<DOCNO>NCT00193297</DOCNO>
	<brief_summary>The purpose study evaluate feasibility toxicity combination paclitaxel , carboplatin , topotecan patient previously untreated , stage III IV epithelial ovarian carcinoma primary peritoneal carcinoma . We also make preliminary evaluation efficacy three drug regimen initial treatment patient .</brief_summary>
	<brief_title>Topotecan Plus Paclitaxel Carboplatin Initial Treatment Advanced Ovarian Primary Peritoneal Carcinoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Paclitaxel + Carboplatin + Topotecan maximum six course chemotherapy give 21 day interval</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Epithelial ovarian carcinoma primary peritoneal carcinoma Willing consider secondlook surgery evaluate response necessary No previous treatment chemotherapy radiation therapy Ability perform activity daily live minimal assistance Adequate bone marrow , liver kidney function Written inform consent You participate study follow apply : Age &lt; 18 year Brain metastasis Recent history significant heart disease within 6 month Other significant medical condition Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Ovary Cancer</keyword>
</DOC>